EUCTR2011-003767-29-ES进行中（未招募）不适用
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol - Combining Lesinurad with Allopurinol in Inadequate Responders (CLEAR 2)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subject is able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity.
- •-Subject meets the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.
- •-Subject has been taking allopurinol as the sole urate-lowering therapy indicated for the treatment of gout for at least 8 weeks prior to the Screening Visit at a stable, medically appropriate dose, as determined by the Investigator, of at least 300 mg per day (at least
- •200 mg for subjects with moderate renal impairment).
- •-Subject must be able to take gout flare prophylaxis with colchicine or an NSAID (including Cox-2 selective NSAID) ±PPI.
- •-Subject has an sUA level >or= 6.5 mg/dL at the Screening Visit and Day -7 Visit.
- •-Subject has reported at least 2 gout flares in the prior 12 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 725
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •-Subject with known hypersensitivity or allergy to allopurinol.
- •-Subject who is taking any other approved urate-lowering medication that is indicated for the treatment of gout other than allopurinol within 8 weeks of the Screening Visit.
- •-Subject who is pregnant or breastfeeding.
- •-Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
- •-Subject with a history or suspicion of drug abuse within the past 5 years.
- •-Subject that requires or may require systemic immunosuppressive or immunomodulatory treatment.
- •-Subject with known or suspected human immunodeficiency virus (HIV) infection.
- •-Subject with a positive test for active hepatitis B or hepatitis C infection.
- •-Subject with a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer.
- •-Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants.
- •-Subject with uncontrolled hypertension.
- •-Subject with an estimated creatinine clearance < 30 mL/min.
- •-Subject with active peptic ulcer disease requiring treatment.
- •-Subject with a history of xanthinuria, active liver disease, or hepatic dysfunction.
- •-Subject receiving chronic treatment with more than 325 mg of salicylates per day.
- •-Subject taking valpromide, progabide or valproic acid.
- •-Subject who has received an investigational therapy within 8 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit.
- •-Subject with any other medical or psychological condition which might create undue risk to the subject or interfere with the subjects ability to comply with the protocol requirements, or to complete the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas - GAMMAmetastatic adenocarcinoma of the pancreasMedDRA version: 12.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticMedDRA version: 12.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableEUCTR2010-020398-18-SIAmgen Inc.825
进行中（未招募）
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-ESCelgene International II Sàrl485
进行中（未招募）
不适用
Phase 3 Study of SAR302503 in Intermediate-2 and High risk patients with Myelofibrosis de riesgo intermedio de nivel 2 o altoPrimary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosisMedDRA version: 14.0Level: LLTClassification code 10018864Term: Haematopoietic neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001897-25-ESsanofi-aventis recherche & développement225
已完成
3 期
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn*s DiseaseNL-OMON54627Celgene International II Sàrl2
进行中（未招募）
不适用
Phase 3 Study of SAR302503 in Intermediate-2 and High risk patients with MyelofibrosisPrimary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosisMedDRA version: 16.1Level: LLTClassification code 10018864Term: Haematopoietic neoplasm NOSSystem Organ Class: 100000004864EUCTR2011-001897-25-DEsanofi-aventis recherche & développement225